Bruce Donzati has a PhD in pharmacology/neuroscience with 20+ years’ experience in the pharma/bio industry. The majority of his time has been spent in global drug safety but he has also worked in pre-clinical development, toxicology, and various roles in Medical Affairs. Prior to entering the industry, Bruce held several positions performing pre-clinical neuroscience research, mostly in the area of mechanisms of neuronal degeneration. During the past 5 years, Bruce was Head of Drug Safety at Genentech, Inc. before transitioning into a new role at Genentech/Roche as Senior Group Director of Global Pharmacovigilance Regulatory Policy that focuses on: 1) ways to promote proactive, innovative ways to perform and predict drug safety events and 2) address current challenges in pharmacovigilance by interacting with both health authorities and industry colleagues. In addition, Bruce is the current Chair of the Biotechnology Industry Organization (BIO) Pharmacovigilance/Benefit Risk Working Party that also seeks to address current challenges in pharmacovigilance as one industry voice.